Browse medicines, page 5 of 6
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 241–300 of 319 records
Velmanase Alfa-Tycv (Lamzede)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Non-central nervous system manifestations of alpha-mannosidosis
Eculizumab-Aeeb (Bkemv)
Protein medicineApproved in the United States (FDA)Expanded recordMirvetuximab Soravtansine-Gynx (Elahere)
Protein medicineApproved in the United States (FDA)Expanded recordNarsoplimab-Wuug (Yartemlea)
Protein medicineApproved in the United States (FDA)Expanded recordNemolizumab-Ilto (Nemluvio)
Protein medicineApproved in the United States (FDA)Expanded recordNirsevimab-Alip (Beyfortus)
Protein medicineApproved in the United States (FDA)Expanded recordPalifermin (Kepivance)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients.
Pegademase Bovine (Adagen)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Apgf (Nyvepria)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Fpgk (Stimufend)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Jmdb (Fulphila)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Unne (Armlupeg)
Protein medicineApproved in the United States (FDA)Expanded recordPegloticase (Krystexxa)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Chronic gout
Pegunigalsidase Alfa-Iwxj (Elfabrio)
Protein medicineApproved in the United States (FDA)Expanded recordPivekimab Sunirine-Pvzy (Decnupaz)
Protein medicineApproved in the United States (FDA)Expanded recordPolatuzumab Vedotin-Piiq (Polivy)
Protein medicineApproved in the United States (FDA)Expanded recordPoractant alfa (Curosurf)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants
Pozelimab-Bbfg (Veopoz)
Protein medicineApproved in the United States (FDA)Expanded recordRasburicase (Elitek)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The initial management of plasma uric acid levels
Ravulizumab-Cwvz (Ultomiris)
Protein medicineApproved in the United States (FDA)Expanded recordRelatlimab-Rmbw (Opdualag)
Protein medicineApproved in the United States (FDA)Expanded recordReteplase (Retavase)
Protein medicineApproved in the United States (FDA)Expanded recordRomosozumab-Aqqg (Evenity)
Protein medicineApproved in the United States (FDA)Expanded recordSacituzumab Govitecan-Hziy (Trodelvy)
Protein medicineApproved in the United States (FDA)Expanded recordSargramostim (Leukine)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients.
Sibeprenlimab-Szsi (Voyxact)
Protein medicineApproved in the United States (FDA)Expanded recordSomatropin [rdna Origin] (Nutropin)
Protein medicineApproved in the United States (FDA)Expanded recordTagraxofusp-Erzs (Elzonris)
Protein medicineApproved in the United States (FDA)Expanded recordTarlatamab-Dlle (Imdelltra)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
Tebentafusp-Tebn (Kimmtrak)
Protein medicineApproved in the United States (FDA)Expanded recordTeclistamab-Cqyv (Tecvayli)
Protein medicineApproved in the United States (FDA)Expanded recordTisotumab Vedotin-Tftv (Tivdak)
Protein medicineApproved in the United States (FDA)Expanded recordTrastuzumab-Pkrb (Herzuma)
Protein medicineApproved in the United States (FDA)Expanded recordUrokinase (Kinlytic)
Protein medicineApproved in the United States (FDA)Expanded recordUstekinumab-Aauz (Otulfi)
Protein medicineApproved in the United States (FDA)Expanded recordVelaglucerase alfa (Vpriv)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Long-term enzyme replacement therapy
Nogapendekin alfa Inbakicept-Pmln (Anktiva)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
Peginterferon Beta-1a (Plegridy)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )
Pegzilarginase-Nbln (Loargys)
Protein medicineApproved in the United States (FDA)Expanded recordPenpulimab-Kcqx
Protein medicineApproved in the United States (FDA)Expanded recordPrabotulinumtoxina-Xvfs (Jeuveau)
Protein medicineApproved in the United States (FDA)Expanded recordRanibizumab-Eqrn (Cimerli)
Protein medicineApproved in the United States (FDA)Expanded recordRanibizumab-Nuna (Byooviz)
Protein medicineApproved in the United States (FDA)Expanded recordRetifanlimab-Dlwr (Zynyz)
Protein medicineApproved in the United States (FDA)Expanded recordRituximab-Abbs (Truxima)
Protein medicineApproved in the United States (FDA)Expanded recordRituximab-Pvvr (Ruxience)
Protein medicineApproved in the United States (FDA)Expanded recordSebelipase alfa (Kanuma)
Protein medicineApproved in the United States (FDA)Expanded recordTafasitamab-Cxix (Monjuvi)
Protein medicineApproved in the United States (FDA)Expanded recordTalquetamab-Tgvs (Talvey)
Protein medicineApproved in the United States (FDA)Expanded recordTechnetium Tc99m Albumin Aggregated (Pulmotech Maa)
Protein medicineApproved in the United States (FDA)Expanded recordTeprotumumab-Trbw (Tepezza)
Protein medicineApproved in the United States (FDA)Expanded recordTezepelumab-Ekko (Tezspire)
Protein medicineApproved in the United States (FDA)Expanded recordTislelizumab-Jsgr (Tevimbra)
Protein medicineApproved in the United States (FDA)Expanded recordTocilizumab-Aazg (Tyenne)
Protein medicineApproved in the United States (FDA)Expanded recordTocilizumab-Anoh (Avtozma)
Protein medicineApproved in the United States (FDA)Expanded recordTrastuzumab-Anns (Kanjinti)
Protein medicineApproved in the United States (FDA)Expanded recordTrastuzumab-Dkst (Ogivri)
Protein medicineApproved in the United States (FDA)Expanded recordTrastuzumab-Dttb (Ontruzant)
Protein medicineApproved in the United States (FDA)Expanded recordTrastuzumab-Strf (Hercessi)
Protein medicineApproved in the United States (FDA)Expanded recordUblituximab-Xiiy (Briumvi)
Protein medicineApproved in the United States (FDA)Expanded record